Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELAD
- Development stage
- Phase 3
- Administration
- Extracorporeal
01
Overview
**ELAD** is a discontinued proprietary bioartificial, extracorporeal liver-support system developed for acute forms of liver failure. The system used a dialysis-type circuit with four hollow-fiber bioreactor cartridges containing more than 100 billion HepG2/C3A human hepatoblastoma-derived cells. Patient plasma was circulated through the device to provide temporary hepatocyte-like metabolic, synthetic, detoxification, and immunomodulatory support, including secretion of anti-inflammatory proteins and growth factors, with the intended role of bridging patients to native liver recovery or liver transplantation. ELAD did not act through a defined molecular binding target. ([dovepress.com](https://www.dovepress.com/article/download/42372))
- Brand names
- ELAD
- Other names
- ELAD SystemExtracorporeal Liver Assist DeviceExtracorporeal Liver Assist SystemVitaGen Extracorporeal Liver Assist Device
Beyond the preview
Go deeper on ELAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELAD.